$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000154422718000007 Filed on August 09, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$55.00K	$81.00K	$84.00K
YoY Change	-1.79%	-3.57%	-55.56%
Cost Of Revenue	$44.00K	$54.00K	$274.0K
YoY Change	51.72%	-80.29%	-77.78%
Gross Profit	$11.00K	$27.00K	-$190.0K
YoY Change	-59.26%	-114.21%	-81.8%
Gross Profit Margin	20.0%	33.33%	-226.19%
Selling, General & Admin	$4.176M	$2.645M	$10.75M
YoY Change	-17.41%	-75.4%	-4.09%
% of Gross Profit	37963.64%	9796.3%
Research & Development	$1.680M	$2.394M	$4.997M
YoY Change	-58.17%	-52.09%	-16.54%
% of Gross Profit	15272.73%	8866.67%
Depreciation & Amortization	$100.0K	$200.0K	$500.0K
YoY Change	-75.0%	-60.0%	-16.67%
% of Gross Profit	909.09%	740.74%
Operating Expenses	$5.953M	$7.985M	$18.01M
YoY Change	-37.09%	-55.67%	-2.26%
Operating Profit	-$5.898M	-$7.904M	-$17.93M
YoY Change	-37.3%	-55.92%	-1.7%
Interest Expense	$230.0K	$220.0K	-$270.0K
YoY Change	360.0%	-181.48%	3.85%
% of Operating Profit
Other Income/Expense, Net	-$7.000K	-$19.00K	$25.00K
YoY Change	133.33%	-176.0%	-213.64%
Pretax Income	-$5.679M	-$7.703M	-$18.17M
YoY Change	-39.3%	-57.61%	-1.86%
Income Tax	$0.00	$0.00	$13.00K
% Of Pretax Income
Net Earnings	-$5.679M	-$7.703M	-$18.19M
YoY Change	-39.37%	-57.64%	-2.06%
Net Earnings / Revenue	-10325.45%	-9509.88%	-21650.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$35.50	-$48.12	-$113.70
COMMON SHARES
Basic Shares Outstanding	35.79M shares	35.76M shares	35.66M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.40M	$53.60M	$86.60M
YoY Change	-38.71%	-38.11%	-41.37%
Cash & Equivalents	$31.92M	$24.60M	$22.94M
Short-Term Investments	$14.40M	$29.00M	$63.60M
Other Short-Term Assets	$2.600M	$500.0K	$2.500M
YoY Change	36.84%	-80.0%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$48.99M	$54.18M	$89.09M
YoY Change	-36.88%	-39.19%	-40.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$108.0K	$403.0K	$3.956M
YoY Change	-97.0%	-89.81%	-51.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$140.0K	$142.0K	$0.00
YoY Change
Other Assets	$0.00	$24.00K	$23.00K
YoY Change	-100.0%	4.35%	0.0%
Total Long-Term Assets	$248.0K	$1.358M	$4.791M
YoY Change	-94.39%	-71.66%	-44.36%
TOTAL ASSETS
Total Short-Term Assets	$48.99M	$54.18M	$89.09M
Total Long-Term Assets	$248.0K	$1.358M	$4.791M
Total Assets	$49.23M	$55.53M	$93.89M
YoY Change	-39.98%	-40.85%	-40.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$604.0K	$757.0K	$3.275M
YoY Change	-77.55%	-76.89%	32.81%
Accrued Expenses	$3.277M	$3.990M	$9.000K
YoY Change	-47.25%	44233.33%	-99.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.881M	$4.747M	$11.82M
YoY Change	-56.41%	-59.84%	10.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$442.0K	$576.0K	$925.0K
YoY Change	-47.0%	-37.73%	-33.93%
Total Long-Term Liabilities	$442.0K	$576.0K	$925.0K
YoY Change	-47.0%	-37.73%	-33.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.881M	$4.747M	$11.82M
Total Long-Term Liabilities	$442.0K	$576.0K	$925.0K
Total Liabilities	$4.323M	$5.323M	$12.74M
YoY Change	-55.6%	-58.23%	4.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$322.2M	-$316.6M	-$283.6M
YoY Change	9.99%	11.62%	36.19%
Common Stock	$36.00K	$36.00K	$36.00K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.91M	$50.21M	$81.14M
YoY Change
Total Liabilities & Shareholders Equity	$49.23M	$55.53M	$93.89M
YoY Change	-39.98%	-40.85%	-40.85%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$5.679M	-$7.703M	-$18.19M
YoY Change	-39.37%	-57.64%	-2.06%
Depreciation, Depletion And Amortization	$100.0K	$200.0K	$500.0K
YoY Change	-75.0%	-60.0%	-16.67%
Cash From Operating Activities	-$7.730M	-$4.830M	-$12.09M
YoY Change	-24.95%	-60.05%	-24.06%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	$150.0K	$20.00K
YoY Change	-1600.0%	650.0%	-96.0%
Acquisitions
YoY Change
Other Investing Activities	$14.90M	$9.860M	$10.00M
YoY Change	26.49%	-1.4%	-73.53%
Cash From Investing Activities	$15.05M	$9.710M	$9.970M
YoY Change	27.98%	-2.61%	-73.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-7.730M	-4.830M	-12.09M
Cash From Investing Activities	15.05M	9.710M	9.970M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	7.320M	4.880M	-2.120M
YoY Change	401.37%	-330.19%	-102.81%
FREE CASH FLOW
Cash From Operating Activities	-$7.730M	-$4.830M	-$12.09M
Capital Expenditures	-$150.0K	$150.0K	$20.00K
Free Cash Flow	-$7.580M	-$4.980M	-$12.11M
YoY Change	-26.48%	-58.88%	-26.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-100000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35789006	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2017Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1542000	USD
CY2018Q2	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1104000	USD
CY2017Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	160000	USD
CY2018Q2	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	59000	USD
CY2017Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	519000	USD
CY2018Q2	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	675000	USD
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2018Q2	ovas	Restructuringand Related Cost Expected Numberof Positions Eliminated Percent RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent	0.50
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	18000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	365769000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366735000	USD
CY2017Q2	ovas	Restructuringand Related Cost Expected Numberof Positions Eliminated Percent RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent	0.50
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2242000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	757000	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5562000	USD
CY2018Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3990000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5562000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3990000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3700000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1860000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	91000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35664000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35653000	shares
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9000	USD
CY2017Q4	us-gaap	Assets Assets	72853000	USD
CY2018Q2	us-gaap	Assets Assets	55533000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.93
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1571000	USD
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2018Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	10400000	USD
CY2018Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	53637000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	22900000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	68781000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	54175000	USD
CY2018Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	100000	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2018Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	300000	USD
CY2017Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	200000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	67203000	USD
CY2018Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	53628000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	27000	USD
CY2018Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	67230000	USD
CY2017Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	10	security
CY2018Q2	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	5	security
CY2018Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	5	security
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22937000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15703000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24601000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	53600000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35725230	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35789006	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35725230	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35789006	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18176000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33070000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7681000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15055000	USD
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	274000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	543000	USD
CY2018Q2	us-gaap	Cost Of Revenue CostOfRevenue	54000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	166000	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	146000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2215000	USD
CY2018Q2	us-gaap	Equity Method Investments EquityMethodInvestments	142000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	951000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000	USD
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	506000	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	100000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	34000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	250000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	2203000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18173000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33059000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7703000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15073000	USD
CY2017Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-454000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-875000	USD
CY2018Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1101000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1485000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3425000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1747000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-996000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	186000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	368000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	224000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	415000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	74000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	55000	USD
	us-gaap	Legal Fees LegalFees	300000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8555000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	5323000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72853000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55533000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7804000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4747000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-20620000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	8897000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6655000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22660000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27275000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13763000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-18186000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33081000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-7703000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	576000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	751000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15073000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	18014000	USD
	us-gaap	Operating Expenses OperatingExpenses	32664000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	7985000	USD
	us-gaap	Operating Expenses OperatingExpenses	15634000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17930000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32517000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7904000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15486000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1126000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	581000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	1311000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	152000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	43476000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	26662000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1578000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547000	USD
	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	0	USD
	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	0	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	50232000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	49253000	USD
CY2017Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	300000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	200000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	221000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.46
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.51
CY2018Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.96
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6813000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2263000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3113000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	403000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4997000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10761000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2394000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5015000	USD
CY2017Q2	us-gaap	Restricted Cash RestrictedCash	812000	USD
CY2018Q2	us-gaap	Restricted Cash RestrictedCash	789000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	44369000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	23749000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16492000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	25390000	USD
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	789000	USD
CY2018Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	789000	USD
CY2018Q2	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	12800000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	1992000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	2000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3480000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3500000	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	2892000	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	2900000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3584000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3600000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	403000	USD
CY2018Q2	us-gaap	Restructuring Reserve RestructuringReserve	513000	USD
CY2018Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	500000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301480000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316552000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10751000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17880000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2645000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6869000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5918000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	912000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.70
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2183106	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4015356	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1179877	shares
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	51500000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	29027000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	64298000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	50210000	USD
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	2200000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35760000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35743000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates and summary of significant accounting policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with US GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in our 2017 Annual Report on Form 10-K.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-18-000007-index-headers.html	Edgar Link	pending
0001544227-18-000007-index.html	Edgar Link	pending
0001544227-18-000007.txt	Edgar Link	pending
0001544227-18-000007-xbrl.zip	Edgar Link	pending
ckretentionagreement.htm	Edgar Link	pending
ckretentionagreement001.jpg	Edgar Link	pending
ckretentionagreement002.jpg	Edgar Link	pending
ckretentionagreement003.jpg	Edgar Link	pending
ckretentionagreement004.jpg	Edgar Link	pending
ckretentionagreement005.jpg	Edgar Link	pending
ckretentionagreement006.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jgretentionagreement.htm	Edgar Link	pending
jgretentionagreement001.jpg	Edgar Link	pending
jgretentionagreement002.jpg	Edgar Link	pending
jgretentionagreement003.jpg	Edgar Link	pending
jgretentionagreement004.jpg	Edgar Link	pending
jgretentionagreement005.jpg	Edgar Link	pending
jgretentionagreement006.jpg	Edgar Link	pending
jgretentionagreement007.jpg	Edgar Link	pending
jgretentionamendment.htm	Edgar Link	pending
jgretentionamendment001.jpg	Edgar Link	pending
jgretentionamendment002.jpg	Edgar Link	pending
jlretentionagreement.htm	Edgar Link	pending
jlretentionagreement001.jpg	Edgar Link	pending
jlretentionagreement002.jpg	Edgar Link	pending
jlretentionagreement003.jpg	Edgar Link	pending
jlretentionagreement004.jpg	Edgar Link	pending
jlretentionagreement005.jpg	Edgar Link	pending
jlretentionagreement006.jpg	Edgar Link	pending
jlretentionagreement007.jpg	Edgar Link	pending
ovas-20180630.xml	Edgar Link	completed
ovas-20180630.xsd	Edgar Link	pending
ovas-20180630x10q.htm	Edgar Link	pending
ovas-20180630xex311.htm	Edgar Link	pending
ovas-20180630xex312.htm	Edgar Link	pending
ovas-20180630xex321.htm	Edgar Link	pending
ovas-20180630xex322.htm	Edgar Link	pending
ovas-20180630_cal.xml	Edgar Link	unprocessable
ovas-20180630_def.xml	Edgar Link	unprocessable
ovas-20180630_lab.xml	Edgar Link	unprocessable
ovas-20180630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2018 Q3 Form 10-Q Financial Statement

#000154422718000007 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2018 Q3 Form 10-Q Financial Statement

#000154422718000007 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst